Methylnaltrexone Pharmacokinetics in Neurointensive Care Patients

Exclusion Criteria

• •History of hypersensitivity to methylnaltrexone (Relistor®)
• •confirmed or suspected obstructive ileus or factors possibly leading to intestinal obstruction (e.g. an intestinal tumor)
• •increased risk for patients with localized or diffused reduction in structural integrity of the gastrointestinal tract (e.g. peptic ulcer, acute diverticulitis)
• •severe hepatic insufficiency (Child-Pugh Class C)
• •renal impairment (glomerular filtration rate \< 90 ml/min) with or without renal replacement therapy
• •severe diarrhea despite high opioid dosing
• •participation in another study with an investigational drug within the 30 days preceding and during the present study